AG-013736 (AXITINIB)
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adenoid Cystic Carcinoma
Conditions
Adenoid Cystic Carcinoma
Trial Timeline
Mar 1, 2012 → Aug 1, 2016
NCT ID
NCT01558661About AG-013736 (AXITINIB)
AG-013736 (AXITINIB) is a phase 2 stage product being developed by Pfizer for Adenoid Cystic Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01558661. Target conditions include Adenoid Cystic Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01558661 | Phase 2 | Completed |
| NCT00919204 | Phase 1 | Completed |
| NCT00282048 | Phase 2 | Completed |
| NCT00071006 | Phase 2 | Completed |
Competing Products
11 competing products in Adenoid Cystic Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfortumab Vedotin | Astellas Pharma | Phase 2 | 52 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| Lenvatinib + Pembrolizumab | Eisai | Phase 2 | 52 |
| P-Sam | AstraZeneca | Phase 2 | 52 |
| Cetuximab | Merck | Phase 1/2 | 41 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Dovitinib | Novartis | Phase 2 | 52 |
| Dovitinib (TKI258) | Novartis | Phase 2 | 52 |
| Regorafenib | Bayer | Phase 2 | 49 |
| Mometasone Furoate nasal spray + Placebo | Organon | Phase 3 | 72 |
| mometasone furoate nasal spray | Organon | Approved | 80 |